You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 128 No. 10, October 1993 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Articles
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Surgical Experience With Pancreatic Islet-Cell Tumors

Charles J. Yeo, MD; Bernadette H. Wang, MD; Gary J. Anthone, MD; John L. Cameron, MD

Arch Surg. 1993;128(10):1143-1148.


Abstract

Objective
To review the surgical management of pancreatic islet-cell tumors, with attention to preoperative localization, surgical therapy, and postoperative survival.

Design
Consecutive case series of patients treated surgically for pancreatic islet-cell tumor.

Setting
The Johns Hopkins Hospital, a large teaching hospital in Baltimore, Md, serving both as a primary and tertiary care center.

Patients
Thirty-seven patients with pancreatic islet-cell tumors treated surgically between 1979 and 1990.

Main Outcome Measures
Success of preoperative localization studies, types of operations performed, and postoperative survival.

Results
Preoperative computed tomography correctly localized the tumor in 20 of 34 patients (59%); angiography in 21 of 28 patients (75%), and the combination of computed tomography and angiography in 23 of 28 patients (82%). Benign islet-cell tumors were found in 19 patients, and malignant tumors in 18 patients. Twenty-four patients (65%) had functional tumors. The proportion of patients with nonfunctioning tumors increased from 0% before 1984, to 43% from 1985 to 1990. Surgical therapy was curative in 27 patients and palliative in 10. The most commonly performed operative procedures were tumor enucleation (11 patients [30%]), distal pancreatectomy (10 patients [27%] and pancreaticoduodenectomy (10 patients [27%]). There was no operative mortality. The actuarial survival at 40 months was 100% in patients with benign tumors and significantly lower (66%) in patients with malignant tumors.

Conclusions
This experience from a single institution underscores the role of preoperative localization studies and appropriate surgical management of these rare tumors.

(Arch Surg. 1993;128:1143-1148)



Author Affiliations

From the Department of Surgery, The Johns Hopkins Medical Institutions, Baltimore, Md.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1993 American Medical Association. All Rights Reserved.